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inhibitory action of 
phenothiazinium dyes against 
Neospora caninum
Luiz Miguel pereira1,2, Caroline Martins Mota  3, Luciana Baroni1,  
cássia Mariana Bronzon da costa1, Jade Cabestre Venancio Brochi1, Mark Wainwright4, 
tiago Wilson patriarca Mineo  3, Gilberto Úbida Leite Braga1 & Ana patrícia Yatsuda1,2 ✉
Neospora caninum is an Apicomplexan parasite related to important losses in livestock, causing 
abortions and decreased fertility in affected cows. Several chemotherapeutic strategies have been 
developed for disease control; however, no commercial treatment is available. Among the candidate 
drugs against neosporosis, phenothiazinium dyes, offer a low cost-efficient approach to parasite 
control. We report the anti-parasitic effects of the phenothiaziums Methylene Blue (MB), New 
Methylene Blue (NMB), 1,9–Dimethyl Methylene Blue (DMMB) and Toluidine Blue O (TBO) on N. 
caninum, using in vitro and in vivo models. The dyes inhibited parasite proliferation at nanomolar 
concentrations (0.019–1.83 μM) and a synergistic effect was achieved when Methylene Blue was 
combined with New Methylene Blue (Combination Index = 0.84). Moreover, the phenothiazinium dyes 
improved parasite clearance when combined with Pyrimethamine (Pyr). Combination of Methylene 
Blue + 1,9–Dimethyl Methylene Blue demonstrated superior efficacy compared to Pyrimethamine 
based counterparts in an in vivo model of infection. We also observed that Methylene Blue, New 
Methylene Blue and 1,9–Dimethyl Methylene Blue increased by 5000% the reactive oxygen species 
(ROS) levels in N. caninum tachyzoites. Phenothiazinium dyes represent an accessible group of 
candidates with the potential to compound future formulations for neosporosis control.
Neospora caninum, an obligate intracellular protozoan, belongs to Apicomplexa phylum, such as Plasmodium 
spp and Toxoplasma gondii. It causes neosporosis, a disease strongly correlated to abortion and decreased fertility 
in cattle, costing billions of dollars worldwide1–3. There is no effective commercial treatment for neosporosis, 
despite the efforts of several chemotherapy-focused groups4–6. For example, Artemisinins7–10, Miltefosine11, plant 
extracts12–14, Diamidines15,16, Buparvaquone4,17, organometallic ruthenium complexes18, Thiazolides19,20 were 
evaluated in in vitro and in vivo models with encouraging results. Moreover, polyether ionophore antibiotics21, 
Triazinones22–24, bumped kinase inhibitors25 have also been tested in farm ruminants26.
Based on the promising effects of Methylene Blue (MB) against Plasmodium spp, the etiologic agent of malaria, 
our group determined the efficacy of this molecule on N. caninum, either alone or combined with Pyrimethamine 
(Pyr)27. MB, a phenothiazinium dye, was the first synthetic drug described to cure a patient affected by malaria in 
the XIX century, pioneering work performed by Paul Ehrlich28,29. Indeed, MB was used against Plasmodium until 
the use of Chloroquine and other drugs (massively utilized after the Second World War), which lack some of the 
reversible MB side effects (blue urine and sclera)30,31. During the later 20th/early 21st Centuries, the intense use 
of Chloroquine, Artemisinin, and Pyrimethamine has led to proven cases of Plasmodium resistance, demanding 
novel therapeutic candidates32. Interestingly, no reports of Plasmodium resistance have been reported in exper-
imental MB-based therapies, reviving the dye as an antimalarial drug33. Moreover, phenothiazinium dyes such 
as New Methylene blue and Toluidine Blue O also demonstrated antimicrobial properties34,35, inspiring us to test 
these compounds against N. caninum.
Ehrlich’s brilliant observations, concerning Methylene Blue suggest that other phenothiazinium derivatives 
(New Methylene Blue, Toluidine Blue O, and 1,9-Dimethyl Methylene Blue) may also provide safe, low-cost 
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candidates to treat parasitic diseases. Since the livestock industry is particularly sensitive to costs, inexpensive 
formulations based on phenothiazinium dyes have the potential to improve the outcomes in cattle affected by 
neosporosis. To this end, we have investigated the anti-parasitic effects of the phenothiaziums Methylene Blue, 
New Methylene Blue, 1,9-Dimethyl Methylene Blue and Toluidine Blue O on N. caninum, using in vitro and in 
vivo models.
Results and discussion
Proliferation and combination assays. MB is the most commonly employed phenothiazinium dye, with 
therapeutic potential against malaria both alone and in associations with Artemisinin, Quinine, Chloroquine and 
Pyrimethamine33,36. MB inhibits N. caninum proliferation, with an IC50 of 0.349 μM (27, Table 1). NMB, TBO, and 
DMMB are Methylene Blue derivatives with diverse modifications (Table 1). For example, in NMB, the dimeth-
ylamino- groups of MB are substituted by ethylamino- moieties and two additional methyl groups are inserted in 
the phenothiazinium core next to the ethylamino groups. TBO has one dimethylamino- and one amino group, 
with a methyl group next to the latter. DMMB has the same structure as MB, but with two methyl groups in the 
positions on either side of the ring nitrogen. NMB, DMMB, and TBO inhibited N. caninum proliferation at IC50 
values of 0.058 μM, 0.019 μM and 1.83 μM respectively (Table 1).
The combination of MB with NMB demonstrated a synergistic effect. The IC50 of MB and NMB decreased 
from 0.221 ± 0.048 μM to 0.119 ± 0.05 μM and from 0.069 ± 0.006 μM to 0.021 ± 0.008 μM, respectively, with a 
CI of 0.84 (Fig. 1A; Table 2). However, the combination of MB and DMMB demonstrated an antagonistic effect 
(CI = 1.36), despite the improvement of the inhibitory pattern. The IC50 of MB diminished from 0.394 ± 0.109 
μM to 0.249 ± 0.146 μM and of DMMB from 0.024 ± 0.013 μM to 0.017 ± 0.012 μM (Fig. 1B; Table 2). Although 
a low IC50 was observed when NMB or DMMB was applied alone (Table 1), the combination between these 
compounds was also antagonistic (CI = 1.40). The doses of NMB and DMMB were altered from 0.064 ± 0.018 
μM and 0.021 ± 0.002 μM to 0.040 ± 0.004 μM and 0.016 ± 0.002 μM respectively (Fig. 1C; Table 2). All Pyr 
combinations were antagonistic (Fig. 1D,E). The Pyr IC50 combined with NMB decreased from 0.347 ± 0.044 μM 
to 0.301 ± 0.077 μM whereas NMB decreased 0.072 ± 0.012 μM to 0.053 ± 0.018 μM, with a CI of 1.60 (Fig. 1D; 
Table 2). When Pyr was combined with DMMB (CI = 1.78) the IC50 doses decreased from 0.436 ± 0.184 μM 
to 0.377 ± 0.159 μM and from 0.029 ± 0.012 μM to 0.026 ± 0.016 μM, respectively (Fig. 1E; Table 2). Due to its 
higher inhibitory concentration (1.83 μM), TBO was not tested in combination assays. The combinations based 
on phenothiazinium dyes demonstrated different patterns of efficiency, which indicates that their mechanisms of 
action might be different and the molecules might interact or accumulate differently when combined. Therefore, 
novel assays concerning the mechanisms of action of phenothiazinium dyes in N. caninum will be required in 
future approaches. Although Pyr is a promising candidate against N. caninum6,27, the NMB, MB and DMMB 
combinations were superior when compared to Pyr counterparts in proliferation assays.
Dyes and Pyrimethamine induces resistance in parasites under selection. All analyzed com-
pounds induced parasite resistance after three rounds of selection (Fig. 2A,C,E,G,I), despite the different 
Name Structure MW IC50 μM CC50 μM SI
MB 319.85 0.349 * >62.5 * >179.1*
NMB 347.91 0.048 ± 0.012 21.893 ± 7.851 456.1
DMMB 416.05 0.019 ± 0.004 8.524 ± 3.317 448.6
TBO 305.83 1.83 ± 0.124 >25 >13.6
Table 1. In vitro IC50 and toxicity of MB, NMB, DMMB, and TBO to N. caninum and Vero cells. The IC50, CC50, 
and selectivity index were calculated for NMB, DMMB, and TBO on N. caninum and Vero cells. Tachyzoites or 
Vero cells were incubated for 72 h, at 37 °C, with 5% CO2, and the proliferation (tachyzoites) or toxicity (Vero 
cells) was measured after CRPG or MTT assays respectively. The percentage of inhibition was calculated in 
comparison to the non-treated controls in three independent assays. *27.
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capacities to inhibit the tachyzoites proliferation (Fig. 2B,D,F,H,J). After the first or the second rounds of selec-
tion, each compound demonstrated different patterns of inhibition and resistance. The highest concentration of 
dyes (MB, NMB, TBO, and DMMB) applied in non-selected parasites (control curves, inverted triangles) inhib-
ited > 90% of the parasite proliferation, whereas Pyr inhibited ~90%, as previously described9,27. MB induced a 
crescent parasite resistance after the successive rounds of selection (Fig. 2A), the same was observed for TBO 
(Fig. 2E) and DMMB (Fig. 2G). After the first, second and third rounds of selection with MB, ~ 85%, 60% and 
Figure 1. Inhibitory activity of phenothiazinium dye combinations against N. caninum. Tachyzoites were 
incubated with seven dilutions (2 × IC50, 1.6 × IC50, 1.3 × IC50, IC50, 0.7 × IC50, 0.5 × IC50, 0.2 × IC50) of 
NMB + MB (A), DMMB + MB (B), DMMB + NMB (C), NMB + Pyr (D) and DMMB + Pyr (E) and the 
proliferation measured after CPRG assay. As references, isolated compounds of each combination were 
evaluated concomitantly in the same plate. The inhibition percentage was calculated in comparison to the non-
treated group and the IC50 and CI values were achieved using Compusyn software.
Combination
(compound 
1 + 2)
IC50 (μM)
(compound 1)
IC50 (μM)
(compound 2)
IC50 (μM)
(combination in 
relation to compound 1)
IC50 (μM)
(combination in relation 
to compound 2) CI
NMB + MB 0.069 ± 0.006 0.221 ± 0.048 0.021 ± 0.008 0.119 ± 0.05 0.84
DMMB + MB 0.024 ± 0.013 0.394 ± 0.109 0.017 ± 0.012 0.249 ± 0.146 1.36
NMB + DMMB 0.021 ± 0.002 0.064 ± 0.018 0.016 ± 0.002 0.040 ± 0.004 1.40
NMB + Pyr 0.072 ± 0.012 0.347 ± 0.044 0.053 ± 0.018 0.301 ± 0.077 1.60
DMMB + Pyr 0.029 ± 0.012 0.436 ± 0.184 0.026 ± 0.016 0.377 ± 0.159 1.78
Table 2. Values of inhibitory concentrations (IC50) and Combinatory Index of the phenothiazinium 
combinations. The IC50 concentrations of the dyes alone and in combinations were calculated using the 
Compusyn software66. The software was also used for the determination of the CI between the combined 
compounds.
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Figure 2. Resistance induction in N. caninum cultures. N. caninum tachyzoites (NcLacZCAT) were inoculated 
in Vero cells (5 × 105/well) and treated with crescent concentrations of MB, NMB, TBO and DMMB and Pyr 
for 72 h, 37 °C, 5% CO2, in three consecutive rounds (the compound concentration in the first, second and 
third rounds was IC50, 2 × IC50, 4 × IC50, respectively). After each round, the samples were pooled, washed 
and applied for parasite burden evaluation, proliferation assays (in 96 well plates, as performed in item 3.3) 
and inoculated in a fresh Vero culture for the subsequent round. The proliferative assays and parasite burden 
evaluation were performed using CPRG assay and compared to the non-selected controls. (A,C,E), (G,I) 
represent the inhibitory curves of tachyzoites selected with IC50, 2 × IC50, 4 × IC50 (first, second and third 
round, respectively) and incubated with serial dilutions of phenothiazinium dyes or Pyr. (B,D,F,H) represent 
the parasite burden (percentage of inhibition compared to the non-treated control) after each round of 
selection. As a control, non-selected parasites were incubated under the same conditions for all evaluations.
5Scientific RepoRtS |         (2020) 10:7483  | https://doi.org/10.1038/s41598-020-64454-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
30% of parasites were inhibited at higher doses, respectively (Fig. 2A). TBO and DMMB induced different levels 
of resistance, despite the high capacity of inhibition after each round (Fig. 2F,H). As observed for MB, the para-
sites selected with TBO demonstrated a high level of resistance: only 30% of parasites were inhibited by the dye 
after the third round. On the other side, DMMB inhibited > 55% of parasites even under the third round of selec-
tion. NMB showed the lower capacity to inhibit and induce parasite resistance among the analyzed compounds 
(Fig. 2C,D). The parasites selected with the IC50 and 2 × IC50 of NMB maintained a similar susceptibility to the 
dye compared to the non-selected counterparts (Fig. 2C).
Compared to the phenothiazinium dyes (excepting NMB), Pyr demonstrated a delayed resistance induction 
(Fig. 2I), which might be related to a distinct mechanism of action, known to be based on the inhibition of the 
DHFR enzyme37. Due to the single target for action, only part of the DHFR machinery is inhibited by Pyr at IC50 
concentration, maintaining a residual folate metabolism, decreasing the selective pressure. The folate metabolism 
failure induced in higher Pyr concentrations (> 2 × IC50) probably improves the selective pressure, generating 
resistant parasites. On the other side, phenothiazinium dyes have multiple targets of inhibition in Apicomplexa, as 
demonstrated in Plasmodium33. Although the complete mechanism of action of MB and analogs in Plasmodium 
is unclear, the dye inhibits the Glutathione Reductase enzyme38, the polymerization of heme into hemozoin39 and 
also acts as a subversive substrate of antioxidant disulfide reductases40. Nevertheless, future assays related to the 
mechanism of action of dyes in N. caninum will be mandatory to elucidate the lower inhibitory/resistance induc-
tion of NMB compared to MB, TBO, and DMMB. Once all tested compounds induced parasite resistance, the 
use of single-drug therapies is potentially unfeasible for N. caninum using phenothiazinium dyes or Pyr. Indeed, 
for T. gondii, the use of drug combinations is a current and efficient strategy to minimize parasite resistance and 
recrudescence41.
Clearance of parasites. The phenothiazinium dyes demonstrated different patterns for the in vitro clear-
ance of N. caninum. TBO was excluded from the clearance assay due to its high inhibition dose: a toxic effect 
to the host cells would affect the interpretation of the results. For example, concerning the toxic values in cells 
(CC50), the concentrations applied in clearance assays (4 × IC50) were lower for MB (1.6 μM), NMB (0.2 μM) and 
DMMB (0.08 μM) compared to TBO (~ 7.5 μM). Moreover, the value of CC50/4 × IC50 for TBO was 3.3 whereas, 
for MB, NMB and DMMB were 39, 109.4 and 106.5, respectively.
As observed previously for MB27, DMMB and NMB eliminated all extracellular tachyzoites after the fourth 
cycle (Fig. 3A). However, the tachyzoite clearance rate of NMB was delayed compared to DMMB. Whereas 
DMMB eliminated the tachyzoites above 95% in all cycles; NMB diminished the parasite burden in 85% and 82% 
after the first and second cycles, respectively (Fig. 3B). The combinations improved the capacity of DMMB and 
NMB, eliminating all extracellular tachyzoites after the third cycle. Among the compound combinations tested, 
all cycles reached over a 96% clearance rate. The CPRG assay, performed after the fourth cycle, indicated that 
NMB exhibited a higher N. caninum infection rate when compared to DMMB, demonstrating a diminution of the 
parasite burden in 68% and 79% respectively (Fig. 3C). No toxic effects were observed in Vero cells treated with 
compounds or combinations (data not shown). The compound combinations improved the parasite clearance; 
however, a different pattern was observed compared to the proliferation assays. The NMB + MB combination, 
synergistic in the proliferation assays, was inferior in comparison to the MB + DMMB combination. Moreover, 
all combinations of phenothiazinium dyes with Pyr demonstrated a clearance improvement compared to the 
single molecules (Fig. 3C), despite the antagonism observed in proliferation assays. Our previous work indi-
cated a high capacity for parasite clearance under Pyr incubation, which was improved after combination with 
MB27. Moreover, we also observed the low N. caninum clearance capacity of Artemisinin in vitro, demanding 
the use of drug combinations9. Artemisinin is a classic example of drug resistance induction in Plasmodium. 
Thus, Artemisinin-based Combination Therapy (ACT) is strongly recommended for malaria treatment due to 
the emergence of Art-resistant parasites42. Likewise, a similar approach may be considered for N. caninum. Assays 
related to the mechanism of action of phenothiazinium dyes and Pyr are necessary, as there is a clear differ-
ence when compounds are tested in proliferation and clearance assays. Moreover, an adequate description of the 
mechanism of action of phenothiaziniums is also important to establish future formulations against neosporosis, 
prepared to act in a specific phase of the disease (acute, chronic and congenital).
Phenothiazinium dyes increase the ROS levels in tachyzoites. Phenothiazinium dyes have the 
potential to elevate ROS in several cellular models34,43–45. However, the inhibitory concentrations for yeast, bacte-
ria or mammalian cells are usually above 1 μM35,46, whereas against N. caninum the oxidant effects were observed 
at nanomolar levels (Fig. 4A), except for TBO. The effects of TBO in parasites and host cells may be probably 
conflicting due to the higher SI (13.6) compared to MB (179.1), NMB (456.1) and DMMB (448.6).
For N. caninum, NMB, DMMB and MB combinations resulted in a similar ROS level when compared to single 
compounds (Fig. 4A). The higher efficacy of phenothiazinium dye combinations compared to the single regimens 
in proliferation, clearance and in vivo assays do not directly correlate to ROS production. Whilst the dye combi-
nations improved the anti-proliferative pattern, clearance rate and mice protection in comparison to the single 
treatments, ROS production was similar when these treatments were compared. Thus, novel approaches will be 
designed to elucidate the mechanisms for the compound synergism at a molecular level. Compared to single 
compounds, the combination of MB and NMB increased the ROS production in Vero cells significantly (Fig. 4B), 
but proportionally lower than observed in N. caninum (Fig. 4C,D). The compounds elevated the fluorescence 
percentage above 2000% in N. caninum, whereas this reached 163% against Vero cells (Fig. 4C,D), indicating dif-
ferent compound susceptibilities between parasite and host cell. Indeed, there is a relation between ROS elevation 
and inhibition of proliferation in N. caninum (not observed in Vero cells) when incubated with phenothiazinium 
dyes at 4 × IC50. Vero cells incubated with tested compounds at 4 × IC50 doses proliferate normally as verified in 
compound-free controls (data not shown).
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Dyes decrease the mitochondria potential in cultures. The incubation of N. caninum infected or 
non-infected cells with phenothiazinium dyes demonstrated a different pattern in mitochondrial potential com-
pared to Pyr (Fig. 5). At 10 × IC50, all dyes decreased the Mitotracker incorporation, whereas no alteration was 
observed for the non-treated control and Pyr (Fig. 5A,F). Moreover, the reduction of the mitochondrial potential 
has an evident effect in proliferating parasites rather than host cells, as observed in proliferation and clearance 
assays (Table 1 and Fig. 3). Indeed, N. caninum and T. gondii attract mitochondria during the proliferation pro-
cess47–49, a crucial step for parasite survival. Moreover, MB, NMB, TBO, and DMMB decrease the T. cruzi in vitro 
mitochondria potential, impairing the parasite proliferation50. At IC50 concentrations, NMB and TBO (Fig. 5D,E) 
exhibited a similar pattern compared to Pyr or non-treated controls (Fig. 5A,F), corroborating the lower efficacy 
of the dye in clearance and resistance assays. Dyes in higher concentrations (MB and TBO at 10 × IC50) altered 
the parasite organization in vacuoles, indicating a widespread effect in the parasite/vacuole structure (Fig. 5B,E). 
On the other side, no effects in the cell structure were observed in cultures incubated with the compounds under 
the same conditions (Fig. 5). Thus, there are specific and general effects of dyes in vacuoles, dependent on the 
compound structure and/or concentration. For the complete elucidation of the mechanism of action of pheno-
thiazinium dyes and Pyr in N. caninum, novel strategies related to mitochondria activity and parasite/vacuole 
structure will be adopted in future studies.
Figure 3. Clearance of N. caninum in Vero cells. Purified tachyzoites NcLacZCAT (1 × 106/well) were 
incubated with 4 × IC50 of NMB, DMMB and combinations of these compounds with MB or Pyr for 72 h, at 
37 °C, with 5% CO2. The extra-cellular tachyzoites were counted and re-incubated under the same conditions 
for four consecutive rounds. After each cycle, the percentage of parasite clearance was calculated. In the fourth 
cycle, the final parasite burden was detected after incubation with CPRG for 24 h. (A) The absolute number of 
tachyzoites after each cycle; (B) Percentage of clearance after each cycle; (C) Final parasite burden measured by 
CPRG reaction (24 h of incubation).
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Effects of phenothiazinium dyes in an in vivo model. The clearance assay is a more suitable method 
to guide a rational strategy for the treatment of neosporosis in animal models. The clearance assay reveals the 
elimination of parasites from cell culture, whereas proliferation measures the capacity of tachyzoite multiplication 
in the presence of the compound. Therefore, the in vitro clearance assay is similar to in vivo chemotherapy, since 
both methodologies are based on the parasite elimination from a host. Thus, mice infected with N. caninum were 
treated with DMMB alone or in combination with MB or Pyr, which demonstrated the highest in in vitro clear-
ance rates (Fig. 3). TBO and NMB were excluded from the in vivo assays due to the higher SI compared to MB and 
DMMB and due to the lower clearance and mitochondria depolarization capacity, respectively. We based the in 
vivo parameters on articles that analyzed the effects of MB in models using mice36,51–53. MB was tested in different 
doses (2.5 to 2000 mg/Kg) with deleterious effects usually observed in long term treatments (five weeks) using 
doses >100 mg/Kg/day53. However, no studies have ever been performed for assessing the in vivo toxic effects of 
DMMB, demanding complementary toxicological assays. In a murine model of malaria, it was estimated that 
a regimen using MB 45.77 mg/Kg/day eliminates 90% of Plasmodium berghei36. Moreover, the effectiveness of 
intraperitoneal MB (50 and 100 mg/Kg/day) to control the blood stage of Plasmodium yoelii in BALB/c mice was 
also demonstrated54. Thus, for the initial treatment of animals acutely infected with N. caninum, a dose of 50 mg/
Kg/day (MB and/or DMMB) represented a rational choice. We used cerebral neosporosis as a first approach once 
the main features of the compounds (mortality, morbidity, parasite burden, and toxicity) may be assessed before 
the use of more complex models.
On the sixth day after N. caninum infection, 2 out of 6 animals treated with PBS died. Under treatment with 
DMMB 1 out of 6 died after the seventh and eighth days. The DMMB + Pyr combination demonstrated a sim-
ilar result, with 2 animals succumbing after the eighth day. However, all animals (6/6) were protected by the 
combination of DMMB with MB (Fig. 6A) and no evident clinical signs (ruffled coat, apathy, walking disorders, 
rounded back and paralysis) were observed. Despite similar protection of animals treated with DMMB and the 
combination DMMB + Pyr, the cerebral parasite burden from the surviving animals was different. The ratio of 
parasite/host cell DNA in animals treated with DMMB and DMMB + Pyr combination was 4.43 and 0.95 respec-
tively. The DMMB + MB combination reached 0.53, whereas for PBS control the relation was 2.56 (Fig. 6B). 
The combinations demonstrated superior efficacies compared to DMMB applied alone, elevating the surviving 
rate and/or decreasing the parasite burden. The efficacy of DMMB alone for the treatment of infected animals 
demonstrated the limitations of single-compound based chemotherapies. Drugs usually have few therapeutic 
targets, and this is usually insufficient against multiple evasion mechanisms in protozoans such as N. caninum 
or T. gondii55. Moreover, parasite resistance to Pyr has been achieved in N. caninum and T. gondii in culture56,57. 
Surprisingly, compounds from the same class (DMMB and MB) demonstrated superior performance compared 
Figure 4. ROS production in tachyzoites and Vero cells incubated with MB, NMB, DMMB, and combinations. 
Tachyzoites (A,C) and Vero cells (B,D) were incubated with dilutions (4 × IC50) of NMB, MB, DMMB and its 
combinations (4 × IC50) for 30 min, 37 °C, 5% CO2. After the incubation, parasites or cells were washed with 
PBS and incubated with DCFDA (Sigma) for 15 min, 37 °C, 5% CO2 in the dark. Samples were analyzed in a BD 
FACS-Canto cytometer and the fluorescence intensity median achieved (A,B). The percentage of fluorescence 
was also calculated, compared to the no compound control (C,D). *p < 0.05.
8Scientific RepoRtS |         (2020) 10:7483  | https://doi.org/10.1038/s41598-020-64454-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
to combinations based on compounds belonging to different categories (DMMB and Pyr), indicating possibly 
more than one mechanism of action among phenothiazinium dyes against N. caninum. Once the synergistic 
phenomena observed in the proliferation (NMB + MB) and in vivo approaches (DMMB + MB) have been not 
observed in Apicomplexa, further studies will be required. No toxic effects were observed (apathy, weight loss, 
behavior) in treated animals for 30 days. However, complementary assays such as dose-dependent treatment, 
use of alternative routes of administration and/or infection will be required to determine a safe application level 
of these compounds/combinations for clinical use. The data from the acute model of infection, as applied in this 
study, is an initial approach and usually will be useful for future testing in chronic and congenital models.
The combinations of MB with NMB or DMMB demonstrated synergism in vitro or in vivo respectively, which 
is usually observed when effective compounds from different families are combined58. Thus, further work will be 
performed to investigate the common and exclusive targets of phenothiazinium dyes. Moreover, the effectiveness, 
pharmacodynamics, half-life, and clearance of each compound (and the combinations) are fundamental points 
for the design of future clinical strategies. Despite the absence of toxic effects in the host cell in all assays using 
MB, NMB and DMMB, complementary strategies to clarify the side effects of these compounds and formulations 
will be demanded. Since there is no data concerning the use of phenothiazinium dyes for the treatment of food 
animals, our study describes a new potential form to control neosporosis. The use of low-cost compounds, such 
as phenothiazinium dyes against neosporosis, represents a suitable form for livestock management, improving the 
productivity of the cattle and impacting the economy of beef and dairy industry worldwide.
Methods
Neospora caninum. N. caninum Nc1 expressing β-galactosidase (NcLacZCAT)59 was used in proliferation 
and clearance assays. For oxidative stress assays, Nc1 purified tachyzoites (using 5 μm syringe filtration) were 
employed. In the in vivo model of infection, the virulent N. caninum Liverpool strain (NcLiv) was used. NcLiv 
was cultivated in Vero cell monolayers for 30 passages when it was inoculated in C57Bl/6 mice to improve its 
virulence. The in vivo assay was performed using NcLiv cultures at the 20th passage.
Figure 5. Effects of dyes in parasitophorous vacuoles and mitochondria. Tachyzoites (2 ×105/well in 24 well 
plates) were incubated in Vero cell monolayers and incubated for 48 h, 37 °C, 5% CO2. The cultures were treated 
with the IC50 and 10 × IC50 of MB, NMB, TBO, DMMB and Pyr for 24 h, 37 °C, 5% CO2. Similarly, non-infected 
Vero cell cultures were incubated with dyes and Pyr under the same conditions. After washing, fixation, 
blocking and labeling with anti-N. caninum serum (Alexa 488, ex/em: 490/525), Mitotracker (ex/em: 579⁄599) 
and DAPI (ex/em: 358⁄461), the cultures were analyzed using confocal microscopy. The figures were composed 
by MT (Mitotracker), anti-Nc (anti-N. caninum serum), merge DAPI (Mitotracker + anti-Nc + DAPI) and 
merge w/ bright-field (Mitotracker + anti-Nc + DAPI + bright field) images. (A) Non-treated control; (B) MB 
treated; (C) DMMB treated; (D) NMB treated; (E) TBO treated; (F) Pyr treated. Bars indicate 10 μm.
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Pyrimethamine and phenothiazinium dyes. Methylene Blue ([7-(dimethylamino)phenothiazin
-3-ylidene]-dimethylazanium;chloride, catalogue number: 1428008), New Methylene Blue (ethyl-[7-(ethyl-
amino)-2,8-dimethylphenothiazin-3-ylidene]azanium;chloride, catalogue number: R313718), Toluidine Blue 
O ((7-amino-8-methylphenothiazin-3-ylidene)-dimethylazanium;chloride, catalogue number: T3260), 1,9 – 
Dimethyl-Methylene Blue ([7-(dimethylamino)-1,9-dimethylphenothiazin-3-ylidene]-dimethylazanium;chlo-
ride, catalogue number: 341088) and Pyrimethamine (5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine, 
catalogue number: 1589007) were purchased from Sigma-Aldrich and diluted (5 mg/ml each) in PBS (MB, NMB, 
TBO and DMMB) or DMSO (Pyr) for in vitro use. For in vivo application, DMMB, MB and Pyr were diluted 
(2.5 mg/ml) in PBS.
Proliferation assay. The proliferation assay was performed as described in27. Briefly, purified N. caninum 
tachyzoites were distributed (1 × 103/well) in a Vero cell culture in a 96 well plate and incubated for 2 h to allow 
cell invasion. After the invasion process, seven NMB, TBO or DMMB dilutions (starting from 0.25 μM, 20 μM 
and 0.12 μM respectively) were added, in triplicate, to the infected cells and the plates were incubated for 72 h, at 
37 °C with 5% CO2. For the evaluation of the drug combinations, after parasite invasion, seven fractional inhibi-
tory concentrations (2 × IC50, 1.6 × IC50, 1.3 × IC50, IC50, 0.7 × IC50, 0.5 × IC50, 0.2 × IC50), of each compound 
alone or combined were applied on proliferating tachyzoites under the same conditions. The 2 × IC50 concentra-
tions for MB, Pyr, NMB, and DMMB were 0.7, 0.7, 0.125, and 0.05 μM, respectively. The drug combination was 
composed of a solution containing an equal concentration of each compound. As a control, the same concentra-
tion of every single compound was used. After incubation, the wells were washed with PBS and lysed with 125 μl 
CPRG lysis buffer (100 mM 4- (2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 8.0; 1 mM CaCl2; 1% Triton 
X-100, 0.5% SDS; 5 mM DTT) for 1 h at 50 °C. The lysates were incubated with 125 μl of CPRG buffer (5 mM 
CPRG, 5 mM 2-mercaptoethanol in PBS) for 1 h and the plates read at 570 nm in an ELISA reader (Sunrise, 
Tecan). Three independent assays were performed.
Figure 6. In vivo evaluation of DMMB and combinations. C57Bl/6 mice were infected with 1 × 107 N. caninum 
tachyzoites (NcLiv) and after 12 h treated with five single doses of DMMB (50 mg/Kg/day) and its combinations 
with Pyr (10 mg/Kg/day) or MB (50 mg/Kg/day) for five days. The control was composed of infected animals 
treated with PBS. The animals were observed for 30 days and the surviving rate (A) and cerebral parasite burden 
(B) determined. * represent p < 0.05 compared to the PBS group.
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Cytotoxicity. The deleterious effects of the phenothiazinium dyes to the host cells were evaluated by MTT 
assay60 adapted for Vero cells27. Briefly, 5 × 103 Vero cells/well were cultivated in 96 well plates until cell conflu-
ence. The cells were cultured with dilutions of NMB, TBO, and DMMB (starting from 100 μM) for 72 h, at 37 °C, 
with 5% CO2. The treated wells were incubated with MTT solution (500 μg/ml) for 4 h, 37 °C, 5% CO2 followed by 
formazan dilution within acidified isopropanol (HCl 50 mM). The plates were read at 570 nm in an ELISA reader 
(Sunrise, Tecan) and cytotoxicity estimated as previously described27. Three independent assays were performed.
Resistance assay. The resistance assay was schematically described in Supplementary Fig. 1. NcLacZCAT 
tachyzoites (5 × 105/well) were distributed in Vero cell monolayers (cultivated in 24 well plates) and incubated for 
2 h, 37 °C, 5% CO2 for cell invasion. After the invasion, the cultures were washed with PBS and treated with the 
IC50 concentration of phenothiazinium dyes and Pyr (0.5 μM, 0.6 μM, 2 μM, 0.025 μM and 0.5 μM of MB, NMB, 
TBO, DMMB, and Pry, respectively) for 72 h, 37 °C, 5% CO2. The control was incubated with RPMI with 0.05% 
DMSO (similar to Pry treated samples), under the same conditions. The treated samples and the non-treated 
control were pooled in 15 mL tubes, washed with PBS and resuspended in 6 ml of RPMI without phenol red. The 
suspension was divided into three parts. The first part of the suspension (1 ml/tube) was centrifuged (3 minutes, 
2500 g) and applied for the parasite burden evaluation by CPRG assay (24 h of incubation at 37 °C). Likewise, the 
second part of the suspension was applied in proliferation assays as described in item 3.3. The selected parasites 
(125 μl/well) were inoculated in duplicate in 96 well plates containing Vero cell monolayers. The plates were incu-
bated for 2 h, 37 °C, 5% CO2 for cell invasion and treated with seven serial dilutions of dyes and Pyr. The higher 
concentrations of MB, NMB, TBO, DMMB, and Pry applied in proliferation assays were 5 μM, 1 μM, 10 μM, 0.1 
μM, and 5 μM respectively. The plates were incubated for 72 h, 37 °C, 5% CO2 and analyzed by CPRG assay, as 
described in item 3.3. From CPRG assays, the percentage of inhibition in comparison to the non-treated samples 
was calculated and plotted. Finally, the third part of the suspension of 3 ml (1 ml/well) was inoculated in fresh 
Vero cell monolayers, as performed in the first round of selection. In the second round of selection, the cultures 
were treated with 2 x IC50 of phenothiazinium dyes and Pyr. After the second round of selection, the samples were 
analyzed as described for the first one. Finally, the third round of selection was also performed under the same 
conditions using 4 × IC50 of phenothiazinium dyes and Pyr and analyzed as previously described. Two independ-
ent assays were performed.
Clearance assay. Clearance assays were performed as previously described27. Briefly, purified tachyzoites 
(NcLacZCAT, 1 × 106/well) were allowed to invade Vero cells monolayers, cultured in 24 well plates, for 2 h, at 
37 °C, with 5% CO2. After the invasion, NMB, DMMB, and combinations of these compounds with MB or Pyr 
(4 × the IC50 of each one) were added and incubated for 72 h, at 37 °C, with 5% CO2. After this, the cultures were 
detached and the extracellular tachyzoites counted in a hemocytometer. The remaining tachyzoites were incu-
bated in a new Vero cell culture under the same conditions. Four consecutive cycles of incubation were performed 
and the inhibition percentage and the absolute number of tachyzoites were calculated. Finally, the final parasite 
burden was measured after incubation with CPRG for 24 h as described in the proliferation assay.
Evaluation of oxidative stress in tachyzoites. Tachyzoites (Nc1 strain) and Vero cells were used in 
oxidative stress assays. Purified tachyzoites (1 × 106/tube) or cells (a confluent culture in a 24 well plate, in dupli-
cate), in RPMI without phenol red, were incubated with 4 × IC50 of MB (1.6 μM), 4 × IC50 of NMB (0.25 μM) 
and 4 × IC50 of DMMB (0.1 μM) for 30 min at 37 °C with 5% CO2. Additionally, these dyes were combined 
(MB + NMB; MB + DMMB; NMB + DMMB) and applied to parasites or cells under the same conditions. After 
the incubation, tachyzoites, and cells were washed twice with PBS and processed for flow cytometry analysis. 
Cells were incubated with 0.05% trypsin in PBS (Life Technologies) supplemented with 2 μM DCFDA (Sigma) 
for 30 min, at 37 °C, with 5% CO2 in the dark. Tachyzoites were incubated under the same conditions; however 
without a trypsinization step. The median fluorescence intensity (from gates representing cells or tachyzoites) was 
measured in a BD FACS-Canto (BD Biosciences) flow cytometer (Ex.488/Em.535 nm) with the FACSDiva (BD) 
6.1.3 software. The fluorescence percentage was calculated in relation to the non-treated group. Two independent 
experiments were performed for each assay.
N. caninum structure and mitochondrial potential in parasitophorous vacuoles. For confocal 
analysis, tachyzoites were inoculated (2 × 105/well) over Vero cell monolayers in 24-well plates with coverslips 
at the bottom and incubated during 48 hours for invasion and proliferation. After incubation, the cultures were 
treated with IC50 and 10 × IC50 of MB (0.5 μM / 5 μM), NMB (0.06 μM / 0.6 μM), TBO (2 μM / 20 μM), DMMB 
(0.02 μM / 0.2 μM) and Pyr (0.5 μM / 5 μM) for 24 h at 37 °C and 5% CO2. The supernatants were discarded and 
400 nM Mitotracker (Mitotracker Red CMXRos, Invitrogen, Thermo Fisher Scientific, OR, USA) were added to 
the wells and incubated for 20 minutes at 37 °C and 5% CO2. The supernatants were discarded and the wells were 
washed twice with PBS. Then, the cells were fixed with 3.7% formaldehyde, followed by permeabilization (0.2% 
Triton X-100) and blocking (2% bovine serum albumin; 20 mM glycine). The nuclei were observed using 300 nM 
4′,6-diamidino-2-phenylindole (DAPI, Molecular Probes, Life Technologies, OR, USA). N. caninum was detected 
with serum anti-N. caninum (1:1,000) and anti-mouse conjugated with Alexa 488 (5 µg/ml; Molecular Probes, 
Life Technologies, OR, USA). The anti-N. caninum serum was generated in BALB/c animals (CEUA-FCFRP, 
process 17.5.278.60.8), detailed in the Supplementary Material (Supplementary Material 2). The coverslips were 
mounted on a slide and sealed with liquid blocker (Super PAP Pen mini, Doido Sangyo Co. Ltd., Tokyo, Japan). 
The slides were observed in a TCS-SP8 AOBS (Leica Microsystems), using a 63 X objective and processed by 
ImageJ software (National Institute of Health, USA). The excitation/emission wavelengths for Mitotracker, DAPI 
and Alexa 488 were 579⁄599 nm, 358⁄461 nm, and 490/525 nm, respectively.
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In vivo neosporosis model for treatment. For the in vivo model of infection, six-week-old male C57Bl/6 
mice were used (6 animals/group), according to the local Animal Ethics Committee, approved by the animal 
research committee at Universidade Federal de Uberlândia (UFU) (Comitê de Ética na Utilização de Animais 
da UFU – CEUA/UFU), under protocol number 109/16. The treatment strategy was based on previous stud-
ies performed with N. caninum4,13,14,17,61. The animals were intraperitoneally (i.p.) infected with 1 × 107 NcLiv 
tachyzoites at day 0 and after 12 h the animals were treated with each compound and their combinations. Single 
doses of DMMB (50 mg/Kg/day, i.p.) or combinations of this dye with Pyr (10 mg/Kg/day, oral gavage) or MB 
(50 mg/Kg/day i.p.) were administered during five days. A dose of Pyr was chosen which is insufficient to cure 
the animal against the disease caused by T. gondii62 and was suitable as a parameter for the drug combination 
studies. The non-treated control received only PBS. Animals were observed daily for clinical signs (ruffled coat, 
apathy, walking disorders, rounded back, and paralysis), and mortality during 30 days post-infection. After 30 
days of challenge, surviving animals were euthanized and the brain tissues (20 mg) were collected for parasite 
quantification using real-time PCR (SYBR green detection system; GoTaq qPCR Master Mix, Promega), as pre-
viously described63,64. The genomic DNA was extracted using (Wizard SV Genomic DNA kit, Promega) and 
the concentration normalized to 40 ng/μl (Nanodrop Lite, Thermo Scientific). N. caninum DNA was amplified 
(StepOnePlus, Thermo Scientific) using primers Nc5 (sense 3′ GCTGAACACCGTATGTCGTAAA 5′; anti-
sense 3′ AGAGGAATGCCACATAGAAGC 5′) and normalized using primers for mouse GAPDH (sense 3′ 
CTCGTCCCGTAGACAAAATGG 5′; antisense 3′ AATCTCCACTTTGCCACTGCA 5′). The cerebral parasite 
burden was calculated by interpolation from a standard curve established from serial dilutions of DNA extracted 
from tachyzoites.
Statistical analyses. The percentages of proliferation and toxicity were calculated using the mean absorb-
ance of the compound-free control and the absorbance from each treatment as described previously27. The IC50 
and the combination index (CI) were obtained using Compusyn software (http://www.combosyn.com/) and the 
selective index (CC50/IC50) was also determined. From CI values, synergism (CI < 1) and antagonism (CI > 1) 
interactions were generated65. For clearance, oxidative stress and in vivo (parasite burden) assays, data were ana-
lyzed by one-way ANOVA followed by a Tukey’s post hoc test (compared to non-treated groups) on GraphPad 
5.0 software.
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